Browse the evidence

Non-responders to the PF regimen demonstrated only transient and limited metabolic shifts.

Understanding the differences in metabolic responses can guide dietary strategies for T2D management.

Mitochondrial dysfunction plays a pivotal role in the onset and progression of diabetes.

Understanding mitochondrial dysfunction can guide therapeutic strategies for diabetes management.

Innovative therapeutic strategies are needed to address mitochondrial dysfunction in diabetes.

Practitioners should consider new therapies targeting mitochondrial function in diabetes care.

A shift towards reduced carbohydrate intake and increased dietary fat may be linked to higher morbidity and mortality rates in patients with diabetes.

Practitioners should consider the implications of dietary fat and carbohydrate ratios in diabetes management.

The majority of animal studies demonstrated a greater impact from high-fat diets compared with higher-sugar diets.

Animal studies suggest that high-fat diets may pose greater risks than high-sugar diets, informing dietary recommendations.

A plant-based diet is associated with an increased risk of higher TyG in women (OR = 1.25 for PDI and OR = 1.55 for hPDI).

Practitioners should be cautious about recommending high plant-based diets for women without considering overall dietary balance.

People in Northern China often consume more plant-based foods.

Understanding local dietary habits can inform nutritional guidance and interventions.

Participants assigned a plant-based diet for phase 1 did not see an increase in TMAO during their subsequent animal-meat phase.

Dietary sequencing may influence TMAO levels and cardiovascular risk.

Around 50 significant metabolites and 12 significant microbiota genera correlated with TMAO.

Understanding these correlations may help in developing targeted therapies for CVD prevention.

Orlistat's peak concentration stayed below 5 ng/mL, indicating minimal systemic absorption.

The low systemic absorption suggests a reduced risk of systemic side effects from orlistat.

Barriers to treatment for obesity-related hypertension include obesity stigma, limited access to healthcare, and adherence problems.

Addressing stigma and improving access to care are crucial for effective management of obesity-related hypertension.

The prevalence of obesity has increased four-fold over the four preceding decades, with concomitantly rising rates of hypertension.

Healthcare providers should be aware of the significant rise in obesity and hypertension prevalence.

Sub-chronic administration of 0839 and 0833 reduced food intake and body weight in DIO mice and rats.

These compounds may help in managing weight in populations with diet-induced obesity.

No significant differences in efficacy and safety of the drugs were found between age groups.

Efficacy and safety of these drugs appear consistent, regardless of age.

Tirzepatide has a favorable safety profile but requires further investigation.

Practitioners should consider tirzepatide as a treatment option while monitoring for adverse reactions.

Ambulatory blood pressure monitoring strengthens the association between blood pressure control and cardiovascular outcomes.

Utilizing ambulatory BP monitoring may improve cardiovascular risk assessment in patients treated with GLP-1RA.

Amylin receptor activators may have an adverse effect profile more favorable than that of GLP-1 receptor activators.

Amylin receptor activators may be a safer alternative to GLP-1 receptor activators for patients.

Grip strength declined by 38% following semaglutide treatment.

Monitoring grip strength may be important in patients receiving GLP-1RA therapy to assess muscle function.

Key therapeutic areas include innovative approaches for monogenic disorders, incretin mimetics, dual receptor agonists, microbiome analysis, and improved behavioural interventions.

Practitioners should consider these therapeutic areas for advancing treatment options.

Rates of obesity are projected to continue to increase, with severe obesity expected to be the most common body mass index category for women in the coming decade.

Practitioners should be aware of the increasing prevalence of obesity among women and its implications for health.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is very common in individuals with type 2 diabetes.

Healthcare providers should be aware of the high prevalence of MASLD in their diabetic patients.

The etiology of obesity is multifactorial, and long-term weight maintenance remains challenging.

Interventions for obesity must consider the multifactorial nature of the condition.

Adverse effects of tirzepatide are most often mild and well tolerated, with no significant impact on patients’ quality of life.

Tirzepatide may be a safe option for patients concerned about side effects.

Dual agonists provide additive and potentially synergistic metabolic benefits through complementary receptor activation.

Practitioners may explore the use of dual agonists for enhanced metabolic outcomes in patients.